Synthesis of highly substituted nitropyrrolidines, nitropyrrolizines and nitropyrroles via multicomponent-multistep sequences within a flow reactor

Article abstract of DOI:10.3987/COM-10-S(E)77

We expand upon recent results concerning dipolar cycloaddition reactions of unstabilized azomethine ylids with nitro alkenes to generate 3-nitropyrrolidines via a flow chemistry sequence. This new work describes the development of a three-component coupling reaction between glycine esters, aldehydes and nitro alkenes. In order to further demonstrate the utility of flow technology in concert with heterogeneous reagents and scavengers for complex reaction sequences an in-line oxidation resulting in the conversion of tetra-substituted pyrrolidines to their pyrrole congeners has been developed. The Japan Institute of Heterocyclic Chemistry.

Full text of DOI:10.3987/COM-10-S(E)77

HETEROCYCLES, Vol. 82, No. 2, 2011
1297
HETEROCYCLES, Vol. 82, No. 2, 2011, pp. 1297 - 1316. © The Japan Institute of Heterocyclic Chemistry
Received, 28th June, 2010, Accepted, 29th July, 2010, Published online, 2nd August, 2010
DOI: 10.3987/COM-10-S(E)77
SYNTHESIS OF HIGHLY SUBSTITUTED NITROPYRROLIDINES,
NITROPYRROLIZINES
AND
NITROPYRROLES
VIA
MULTICOMPONENT-MULTISTEP SEQUENCES WITHIN A FLOW
REACTOR
Marcus Baumann,a Ian R. Baxendale,a Andreas Kirschning,b Steven V. Ley,a
and Jens Wegnera,b
aInnovative Technology Centre, Department of Chemistry, University of
Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK, e-mail:
b
theitc@ch.cam.ac.uk; Institute of Organic Chemistry, Leibniz University of
Hannover, Schneiderberg 1B, 30167 Hannover, Germany
Abstract – We expand upon recent results concerning dipolar cycloaddition
reactions of unstabilized azomethine ylids with nitro alkenes to generate
3-nitropyrrolidines via a flow chemistry sequence. This new work describes the
development of a three-component coupling reaction between glycine esters,
aldehydes and nitro alkenes. In order to further demonstrate the utility of flow
technology in concert with heterogeneous reagents and scavengers for complex
reaction sequences an in-line oxidation resulting in the conversion of
tetra-substituted pyrrolidines to their pyrrole congeners has been developed.
‡This paper is dedicated to Prof. Albert Eschenmoser on the occasion of his
85th birthday and in acknowledgement of his many outstanding contributions
to chemistry.
INTRODUCTION
A necessary requirement for modern drug discovery programs is the flexible and rapid access to a large
number of diverse functionalized building blocks.1 These core structures are commonly heterocyclic
motifs which are obtained via a large range of robust chemical transformations. Furthermore, the
heterocyclic frameworks provide readily tunable interactions with biogenic targets to assist optimal
binding data from screening.2 Amongst these heterocyclic structures the pyrrolidine ring has particular
medicinal relevance. It is not only present in many peptide mimetics, but can also be found in numerous

1298
HETEROCYCLES, Vol. 82, No. 2, 2011
drug substances such as levetiracetam3 and vildagliptin4 and other drug candidates including novel PDE9,5
factor Xa,6 rho kinase7 and AKT kinase8 inhibitors. In addition, the pyrrole unit is present in many of the
best selling drugs exemplified by lipitor9 and sutent.10 Based on this evidence we set out to prepare a
series of highly functionalized 3-nitropyrrolidines by means of dipolar cycloaddition chemistry between
nitro alkenes and azomethine ylids using flow microreactor technology.11 Following our previous
experience in this rapidly developing area we anticipated that improved heat and mass transfer (control of
mixing and exotherms),12 safe use of hazardous reagents within the contained reactor system13 and
increased reproducibility when scaling up reactions from milligram to gram operations can be expected.14
The use of in-line purification techniques provided by pre-packed columns of immobilized scavengers or
phase separation methods furthermore facilitates isolation of pure products following solvent removal.15
RESULTS AND DISCUSSION
During initial experiments towards the flow synthesis of 3-nitropyrrolidines we employed commercially
available N-(methoxymethyl)-N-(trimethylsilyl)benzylamine reagent as the reactive dipole precursor
activated upon treatment with an acid catalyst. We used the previously described Vapourtec R2+/R4
system16 where the reagent was dissolved in MeCN (1.0 equiv., 0.5 M) and loaded into one of the two
sample injection loops. This was then combined with a second stream containing the appropriate nitro
alkene (1.0-1.5 equiv., 0.5-0.75 M, in MeCN) and TFA (1.0 equiv., 0.5 M, in MeCN) within a T-mixing
unit. Upon passage of this combined reaction mixture through a heated flow coil (CFC, 10 mL volume,
30-90 min residence time, 60-120 °C) the in situ generated dipole reacted with the olefinic counterpart to
give the desired 3-nitropyrrolidine product. The excess of the nitro alkene, which was used to drive the
reaction to completion within a short residence time, was removed by directing the output of the reactor
coil through a glass column filled with immobilized benzylamine (QP-BZA,17 ~3 equiv.) facilitating
scavenging via a conjugate addition.
Scheme 1. General flow reactor set-up for the synthesis of 3-nitropyrrolidines
To further purify the reaction stream removing colored impurities, a plug of silica gel was placed at the
outlet of the flow stream. Using these conditions the quick assembly of a number of differently
substituted 3-nitropyrrolidines was achieved in good yields and purities after solvent removal only
(Figure 1).

HETEROCYCLES, Vol. 82, No. 2, 2011
1299
O2N
O2N
NO2
N Bn
O
Br
NO2
NO2
N
Bn
O
N
F
S
Bn
OBn
Cl
H
N
Bn
N
Bn
N
Cl
1, 76%
2, 77%
3, 74%
4
5
, 82%
, 79%
Bn
N
NO2
O2N
F3CO
O
NO2
NO2
O
Cl
N
N
Bn
O2N
N
Bn
10
, 93%
N
Bn
Bn
6
, 87%
7
8
9
, 81%
, 91%
, 88%
Figure 1. 3-Nitropyrrolidines prepared via the TFA-method
While we were able to access all these interesting structures there was a need for an improved procedure
since the overall reaction time was prolonged owing to the increased affinity of the pyrrolidine products
to the BZA-scavenger due to formation of TFA salts. As an alternative procedure we prepared a fluoride
ion exchange monolithic cartridge as described in a previous study.18 These ion-exchange monoliths
represent not only cheap and readily prepared polymer-supports, they are also characterized by better
flow parameters (high surface to volume ratio, no solvent-dependant swelling characteristics) and
increased functional loadings when compared to commercial bead format resins. In addition, the use of an
immobilized fluoride source circumvents potential precipitation problems that can occur during the flow
process and obviates the need for TFA as an initiator for the dipole generation. These factors alleviate
many of the safety concerns associate with scale-up.
In order to evaluate the fluoride monolith we used a similar reaction set-up to the one previously
described where two streams of starting materials (stream 1: nitro alkene 1.0-1.5 equiv.; stream 2:
N-(methoxymethyl)-N-(trimethylsilyl)benzylamine 1.0 equiv., both in MeCN) were mixed at a T-piece
and directed into the monolithic cartridge which served as the reactor. A number of the previously
generated 3-nitropyrrolidines (TFA method) was obtained in improved yield and purity using lower
temperatures (Figure 2). Moreover, the overall reaction times could be reduced by 30 minutes as no
binding to the BZA scavenging system was observed. These positive results meant that the range of
substrates could also be rapidly extended to utilize acrylates, vinyl sulfones and vinyl phosphonates as
dipolarophiles.
Bn
N
Bn
N
Bn
N
Bn
N
Bn
O
NO2
N Bn
O2N
N
Br
O
S
O
O
O
N
P
OEt
O
S
Bn
O
O2N
O2N
H
EtO
1
3
9
11
12
, 92%
13
, 83%
14
, 87%
, 83%
, 84%
, 91%
, 86%
Figure 2. 3-Nitropyrrolidines prepared using a fluoride-monolith

1300
HETEROCYCLES, Vol. 82, No. 2, 2011
Intrigued by these two orthogonally differentiated nitrogen moieties presented in the 3-nitropyrrolidines
we furthermore investigated their chemoselective reduction and homolysis. The substrates (dissolved in
EtOH/EtOAC 1:1; 0.1 equiv. HOAc) were passed through the H-Cube flow hydrogenator19 firstly using a
Raney-nickel containing cartridge. Upon premixing the on-board generated hydrogen gas (full hydrogen
mode) and subsequent flow through the Raney-nickel cartridge (10 bar, 60 °C) a selective reduction of
the nitro functionality was achieved to afford 3-aminopyrrolidines (Figure 3; compounds 15, 16, 17, 18)
in very high yields. Additionally, when using a 10% Pd on charcoal cartridge in the flow reactor the
reduction of the nitro group was observed together with simultaneous debenzylation of the inputs giving
good yields of the corresponding diamines (Figure 3; compounds 19, 20, 21). The products of these
reactions can be elaborated by further reaction with acylating or sulfonylating agents, the results of which
will be reported at a later date.20
Cl
OBn
F3CO
Bn
O
NH2
H
NH2
H
N
Bn
N Bn
NH
N
Bn
N
NH
NH
H2N
21
H2N
H2N
17
H2N
H2N
20
15
, 95%
16
, 97%
18
19
, 90%
, 93%
, 97%
, 97%
, 95%
Figure 3. H-Cube hydrogenation of 3-nitropyrrolidines
With these results in hand we wished to expand on the pyrrolidine scaffold by incorporating greater
diversity in the chemical transformation. We chose therefore to make use of stabilized azomethine ylids
derived from readily available glycine imines, which in turn are accessible by condensation of glycine
esters with various aldehydes. The use of such glycine imines in the cycloaddition with electron-deficient
alkenes has been investigated previously in batch mode leading to various diastereomerically or
enantiomerically enriched pyrrolidines through the application of various metal salts such as silver or
lithium21 or chiral auxillaries22 and metal complexes such as Ag-(S)-QUINAP,23 CuI-Segphos24 and
Pd-phosphoramidite.25
However, as these routes26 call for extended reaction times (equivalent to many hours or days) and
usually include the handling and generation of solid materials, which are not deemed to be ideal for
continuous flow processing, we decided to adapt the reported procedures to a more practical method. In
addition, we wanted to interlink the individual steps of imine formation and dipolar cycloaddition by
means of a telescoped sequence. In order to achieve this we prepared stock solutions containing
β-nitrostyrene, benzaldehyde, glycine methylester hydrochloride and triethylamine all dissolved in MeCN.
Each of these solutions was then introduced into a sample loop mounted on the flow reactor and directed
into a heated glass column filled with anhydrous sodium sulfate or magnesium sulfate (typically held at

HETEROCYCLES, Vol. 82, No. 2, 2011
1301
60-80 °C) to promote the imine formation. Upon exiting the drying column the reaction mixture was
directed into a convection flow coil (CFC, 10 mL PFA) heated at 80-100 °C where the cycloaddition
between the nitro alkene and the in situ formed stabilized azomethine ylid takes place (Scheme 2).
Pleasingly, we found that residence times of 20 min in the dehydrating column and 45 min in the CFC
reactor were sufficient to obtain the tetra-substituted nitro-pyrrolidine products in yields greater than 70%
after in-line work-up with the aforementioned benzylamine scavenger (QP-BZA) had removed residual
starting materials. NMR-analysis of this material direct from the reactor revealed that a mixture of
typically three diastereoisomers was formed under thermal conditions albeit with complete regioselective
control. This result is consistent with previous reports.27
Scheme 2. Flow microreactor set-up for the three-component coupling towards nitro-pyrrolidines
Although, these reaction parameters allowed for the rapid generation of the desired nitropyrrolidine
products we were not able to establish conditions to prepare these structures in a diastereomerically pure
form, despite screening different temperatures, reaction times and also utilizing silver or lithium salts
(AgOAc, AgO, LiCl) dispersed on sodium sulfate. Additionally, we observed the formation of a fourth
diastereoisomer by thermally induced epimerization of the stereocenter next to the nitro-functionality as
evidenced by X-ray analysis of compound 22 (Figure 4). As the epimerization occurred under the
standard conditions, i.e. during the 60-90 min in the flow system at a temperature of 80 °C, we anticipate
that epimerization accounts for one diastereoisomer being formed in the synthesis of other
tetra-substituted nitropyrrolidines.
Figure 4. Epimerization for 3-nitropyrrolidine product 22 under thermal conditions

1302
HETEROCYCLES, Vol. 82, No. 2, 2011
In a further extension of this work we wished to not only alter the aldehyde and nitro alkene inputs, but to
also introduce a further point of diversity by modifying the amino acid derived component. For this
reason we chose to use L-proline methyl ester as a readily available alternative to the glycine ester giving
rise to nitropyrrolizine systems which hold interest as novel peptide mimetic structures. Noteworthy,
when applying the previous flow conditions to the multi-component coupling with L-proline methyl ester
we obtained the desired nitropyrrolizine product not only in high yield and purity, but also with good
diastereoselectivity. Careful NMR-analysis on the reaction products still indicated the presence of three
diastereoisomers, however this time in a 10:1:1 ratio as opposed to a 1:1:1 ratio as seen before. Using nOe
experiments we were able to deduce the relative stereochemistry of the major diastereoisomer, which was
later confirmed by X-ray analysis on some of the corresponding HCl-salts (Figure 5). The formation of
the HCl-salt was achieved by adding stoichiometric amounts of HCl (4 M in dioxane) to the product
stream and was found useful not only to obtain single crystals of the nitropyrrolizine product, but also
allowed isolation of a solid material for subsequent storage of these intermediates.
Figure 5. Structures of nitropyrrolizines prepared
Interestingly, when we investigated the synthesis of pyrrolizines using paraformaldehyde, which was
performed as one-pot microwave reaction due to the insolubility of paraformaldehyde, (45 minutes at
80 °C) as aldehyde input we observed lower diastereomeric excesses (27) and in the case of the
quarternary nitro derivative 28 a 1:1 mixture of both diastereoisomers highlighting the importance of
bulkier substituents in order to obtain good diastereoselectivity.

HETEROCYCLES, Vol. 82, No. 2, 2011
1303
Although only a small number of these interesting nitropyrrolizines was prepared both the yields as well
as the diastereomeric ratios seem to be fairly consistent for various inputs. We believe that these
compounds will gain some interest especially as they can be converted into novel amino acid derivatives
by reduction of the nitro group.
Recently, a number of 3,5-diarylpyrrole-2-carboxylates has been described as members of a new
sub-class of histone-deacetylase inhibitors displaying antitumor activity both in vitro and in vivo.28
Consequently, we set out to extend our flow sequence by performing the final aromatization step from the
3-nitropyrrolidines to the corresponding pyrrole derivatives by means of a telescoped oxidation reaction.
In order to conduct this oxidation from the pyrrolidine to the pyrrole a number of heterogeneous oxidants
was investigated by placing them into a glass column situated at the end of the flow stream. Surprisingly,
oxidants such as CrO2 (Magtrieve®) and NiO2 did not generate any of the desired pyrrole product,
nevertheless we found that activated MnO2 (either from commercial sources or freshly prepared29) at
elevated temperatures (85-110 °C) afforded clean conversion to the corresponding pyrroles. We also
found that MeCN was not a suitable solvent in this case as the high temperatures in the MnO2 column led
to solvent break-down forming acetamide as a hydrolysis product. However, when performing the
multi-step sequence in dichloromethane (Scheme 3) no drop in conversion or purity of the resulting
pyrrole products was observed. Consequently, this flow protocol allowed us to conduct a
multi-component flow sequence involving imine formation, ylid-formation, dipolar cycloaddition and the
final oxidation as a single concerted operation.
O2N
R
CFC
O2N
R'
NH2
R
Na2SO4
R
O
R
X
O
O
O2N
R'
DCM
O
+ NEt3
.
OMe
N
H
R'
H
N
OMe
R'
N
OMe
H
H
MnO2
85-110 °C,
30 min
80 °C,
20 min
QP-BZA
80 °C,
45 min
X = NO2, H
OMe
HCl.
H2N
O
Scheme 3. Multistep flow set-up towards nitropyrrole products
Interestingly, analysis by both LC-MS and NMR-spectroscopy indicated two different pyrrole species
were which were identified as the expected 3-nitropyrrole and its des-nitro derivative (Figure 6) which
presumably forms upon formal elimination of nitrous acid as opposed to hydrogen. These results are
consistent with previous literature reports.27,30 The two pyrroles were readily separated using an
automated Biotage SP2 chromatography system allowing for independent characterisation.31

1304
HETEROCYCLES, Vol. 82, No. 2, 2011
O2N
N
O
O2N
O
O
O
N
OMe
MeO
N
OMe
N
N
H
OMe
OMe
MeO
H
H
H
Cl
Cl
F
F
N
29, 22%
30, 20%
31, 20%
32, 24%
OMe
OMe
O
O2N
O
O2N
O
N
OMe
N
N
H
OMe
OMe
H
H
Br
33, 40%
34, 10%
35,21%
30
32 (hydrate)
Figure 6. Structures of 1H-pyrroles prepared by multi-step flow synthesis
One limitation of using manganese dioxide as a heterogeneous oxidant for the conversion of
nitropyrrolidines to the corresponding pyrroles is the only moderate recovery of material despite the
starting material being fully converted to the desired product. Unfortunately, we were not able to obtain
more than a 50-60% isolated yield for this second step. In addition we did not find any evidence for
formation of byproducts, even when washing the MnO2-cartridge with more polar solvents such as
acetone or methanol. We ascribe this finding to the very large surface area of the MnO2 particles leading
to a high affinity for organic substrates, similar to that seen when charcoal is used as a support material in
certain cases.32
Despite this issue the system can be applied to various substrates with success. The process tolerates
different heteroaromatic structures giving the desired pyrroles in reasonable yields albeit in very high
purity.
In summary, new flow chemistry processes have been established to prepare a variety of
3-nitropyrrolidines and nitropyrrolizines via dipolar cycloaddition reactions. These valuable building
blocks were subsequently subjected to flow-mediated diversification protocols either via reduction
pathways or by oxidation to the corresponding pyrroles. Overall, these investigations demonstrate how
new multi-component multistep flow processes can be developed and applied to pharmaceutically
relevant heterocyclic structures clearly highlighting the further value of these flow devices in chemical
synthesis programs.

HETEROCYCLES, Vol. 82, No. 2, 2011
1305
EXPERIMENTAL
Unless otherwise stated reaction solutions were prepared in MeCN or DCM in 20 mL glass vials.
1H-NMR spectra were recorded on a Bruker Avance DPX-400 or DPX-600 spectrometer with residual
13
CHCl3 as the internal reference (CHCl3 H = 7.26 ppm). C-NMR spectra were also recorded in CDCl3
on the same spectrometers with the central peak of the residual solvent as the internal reference (C = 77.0
ppm). COSY, DEPT 135, HMQC, HMBC and nOe spectroscopic techniques were used to aid the
assignment of signals in the 13C-NMR spectra. Infrared spectra were recorded neat on a Perkin-Elmer
Spectrum One FT-IR spectrometer. Letters in the parentheses refer to relative absorbency of the peak: w,
weak, < 40% of the main peak; m, medium, 41-74% of the main peak; s, strong, >74% of the main peak.
LC-MS analysis was performed on an Agilent HP 1100 chromatograph (Luna Max RP column) attached
to an HPLC/MSD mass spectrometer. Elution was carried out using a reversed-phase gradient of
MeCN/water with both solvents containing 0.1% formic acid. The gradient is described in Table 1. For
HRMS a LCT Premier Micromass spectrometer was used.
Table 1. LC-MS conditions
Time/ min
0.00
MeCN/ %
Flow rate/ mL/min
5
95
95
5
1.0
1.0
1.0
1.0
1.0
3.00
5.00
5.50
8.00
5
1-Benzyl-4-(4-bromothiophene-2-yl)-3-methyl-3-nitropyrrolidine, 1:
1
Yield: 76%, tRet = 4.97 min, m/z = 381.0 (M+H+). H NMR (600 MHz, CDCl3):
/ppm 7.27-7.37 (5H, m), 7.15 (1H, s), 6.93 (1H, s), 4.46 (1H, t, J = 7.2 Hz), 3.77
(1H, d, J = 11.4 Hz), 3.71 (2H, s), 3.28 (1H, dd, J = 9.0, 9.6 Hz), 2.72 (1H, dd, J =
9.0, 9.6 Hz), 2.65 (1H, d, J = 11.4 Hz), 1.38 (3H, s); 13C NMR (150 MHz, CDCl3):
O2N
Br
N
S
Bn
/ppm 141.8 (C), 137.7 (C), 129.5 (CH), 128.5 (2CH), 128.4 (2CH), 127.4 (CH), 122.6 (CH), 109.4 (C),
95.9 (C), 63.7 (CH2), 59.4 (CH2), 59.1 (CH2), 47.4 (CH), 23.1 (CH3). IR (neat) ν = 2799.3 (w), 1694.3
(w), 1539.2 (s), 1452.6 (m), 1341.9 (m), 1189.9 (m), 1142.5 (m), 1108.4 (m), 1074.2 (m), 1027.9 (m),
855.7 (m), 833.3 (m), 737.4 (s), 698.4 (s) cm-1. HRMS calculated for C16H18N2O2SBr 381.0272, found:
381.0283.
3-(1-Benzyl-4-nitropyrrolidin-3-yl)-2-chloro-6-methoxyquinoline, 2:
Yield: 77%, tRet = 4.58 min, m/z = 398.1 (M+H+). 1H NMR (600 MHz, CDCl3):
/ppm 8.08 (1H, s), 7.88 (1H, d, J = 9.0 Hz), 7.30-7.40 (6H, m), 7.02 (1H, d, J
O2N
N
Bn
O
= 3.0 Hz), 5.13 (1H, ddd, J = 3.6, 7.8, 12.0 Hz), 4.51 (1H, ddd, J = 3.6, 7.8,
12.0 Hz), 3.94 (3H, s), 3.82 (1H, d, J = 12.6 Hz), 3.75 (1H, d, J = 12.6 Hz),
3.46 (1H, dd, J = 7.8, 10.8 Hz), 3.29 (1H, dd, J = 7.8, 9.0 Hz), 3.24 (1H, dd, J =
N
Cl
4.8, 10.8 Hz), 3.02 (1H, dd, J = 4.8, 9.6 Hz); 13C NMR (150 MHz, CDCl3): /ppm 158.4 (C), 147.6 (C),
142.8 (C), 137.7 (C), 136.0 (CH), 132.2 (C), 129.6 (CH), 128.7 (2CH), 128.6 (2CH), 128.3 (C), 127.5
(CH), 123.3 (CH), 104.9 (CH), 89.2 (CH), 59.1 (CH2), 58.5 (CH2), 58.4 (CH2), 55.6 (CH3), 45.9 (CH). IR

1306
HETEROCYCLES, Vol. 82, No. 2, 2011
(neat) ν = 1666.7 (m), 1622.2 (m), 1591.3 (m), 1549.9 (s), 1495.6 (s), 1453.1 (m), 1346.9 (s), 1230.1 (s),
1166.3 (s), 1046.9 (s), 1026.3 (s), 911.7 (m), 828.8 (s), 731.1 (s), 699.7 (s) cm-1. HRMS calculated for
C21H21ClN3O3 398.1271, found: 398.1279.
2-Benzyl-3a-nitrooctahydro-1H-isoindole, 3:
1
Yield: 74%, tRet = 3.60 min, m/z = 261.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
NO2
7.23-7.35 (5H, m), 3.74 (1H, d, J = 13.2 Hz), 3.70 (1H, d, J = 13.2 Hz), 3.39 (1H, d, J =
10.8 Hz), 2.92-3.05 (3H, m), 2.56 (1H, dd, J = 4.8, 9.0 Hz), 2.12-2.17 (1H, m), 2.06-2.11
(1H, m), 1.84-1.90 (1H, m), 1.55-1.60 (2H, m), 1.47-1.53 (1H, m), 1.43 (2H, t, J = 7.2
N Bn
H
13
Hz); C NMR (150 MHz, CDCl3): /ppm 139.6 (C), 128.4 (2CH), 128.3 (2CH), 127.0 (CH), 95.4 (C),
60.5 (CH2), 59.8 (CH2), 57.4 (CH2), 40.5 (CH), 32.0 (CH2), 27.1 (CH2), 21.6 (CH2), 21.5 (CH2). IR (neat)
ν = 2930.4 (m), 2863.3 (m), 2797.3 (w), 1671.9 (w), 1535.3 (s), 1495.0 (m), 1452.6 (m), 1366.0 (m),
1345.1 (m), 1247.8 (m), 1156.9 (m), 1072.7 (m), 1027.9 (m), 854.4 (s), 737.6 (s), 698.0 (s) cm-1. HRMS
calculated for C15H21N2O2 261.1603, found: 261.1599.
1-Benzyl-3-(2-(benzyloxy)phenyl)-4-nitropyrrolidine, 4:
1
Yield: 79%, tRet = 4.57 min, m/z = 389.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
NO2
7.40-7.50 (5H, m), 7.33-7.38 (4H, m), 7.28-7.32 (3H, m), 6.90-7.05 (2H, m), 5.13 (1H,
ddd, J = 2.4, 4.8, 7.2 Hz), 5.10 (1H, d, J = 11.4 Hz), 5.07 (1H, d, J = 11.4 Hz), 4.29 (1H,
OBn
N
Bn
dt, J = 4.8, 7.8 Hz), 3.70 (1H, d, J = 12.6 Hz), 3.55 (1H, d, J = 12.6 Hz), 3.32 (1H, dd, J =
13
2.4, 11.8 Hz), 3.24 (1H, t, J = 9.0 Hz), 2.80 (2H, t, J = 9.0 Hz); C NMR (150 MHz,
CDCl3): /ppm 156.3 (C), 138.2 (C), 136.3 (C), 129.5 (CH), 128.8 (CH), 128.7 (2CH), 128.6 (CH), 128.4
(2CH), 128.3 (2CH), 128.1 (2CH), 127.9 (C), 127.2 (CH), 121.1 (CH), 112.0 (CH), 90.0 (CH), 70.4
(CH2), 59.3 (CH2), 58.6 (CH2), 58.2 (CH2), 46.0 (CH). IR (neat) ν = 2919.6 (w), 2807.2 (w), 1601.4 (w),
1544.4 (s), 1493.5 (m), 1452.2 (m), 1372.5 (m), 1292.9 (m), 1236.1 (s), 1120.1 (m), 1009.2 (m), 909.7
(m), 748.8 (s), 732.7 (s), 696.2 (s) cm-1. HRMS calculated for C24H25N2O3 389.1865, found: 389.1847.
1-Benzyl-3-(4-chloro-6-fluoro-2H-chromen-3-yl)-4-nitropyrrolidine, 5:
1
Yield: 82%, tRet = 5.64 min, m/z = 389.1 (M+H+). H NMR (600 MHz, CDCl3):
O
NO2
/ppm 7.28-7.38 (6H, m), 7.18 (1H, dd, J = 3.0, 9.0 Hz), 6.89 (1H, dt, J = 3.0, 8.4
Hz), 6.79 (1H, dd, J = 4.8, 9.0 Hz), 4.90 (1H, dt, J = 5.4, 7.8 Hz), 4.84 (1H, d, J =
14.4 Hz), 4.79 (1H, d, J = 14.4 Hz), 4.27 (1H, dt, J = 4.8, 7.8 Hz), 3.73 (1H, d, J =
F
Cl
N
Bn
12.6 Hz), 3.66 (1H, d, J = 12.6 Hz), 3.29 (1H, dd, J = 7.8, 10.2 Hz), 3.11 (1H, dd,
13
J = 5.4, 10.8 Hz), 3.00 (1H, dd, J = 8.4, 9.6 Hz), 2.69 (1H, dd, J = 4.8, 9.6 Hz); C NMR (150 MHz,
CDCl3): /ppm 157.7 (C, d, J = 238 Hz), 149.7 (C), 137.4 (C), 128.9 (C), 128.6 (2CH), 128.5 (2CH),
127.6 (CH), 125.1 (C), 122.9 (C), 116.7 (CH), 116.6 (CH), 111.8 (CH, d, J = 26 Hz), 87.1 (CH), 66.6
(CH2), 59.0 (CH2), 58.0 (CH2), 56.0 (CH2), 44.9 (CH). IR (neat) ν = 2808.7 (w), 1551.6 (s), 1487.3 (s),
1454.3 (m), 1432.2 (m), 1373.0 (m), 1334.6 (m), 1280.0 (m), 1249.8 (m), 1160.6 (s), 1068.9 (m), 1029.1
(s), 982.7 (m), 911.6 (m), 868.3 (m), 817.6 (s), 733.7 (s), 699.0 (s) cm-1. HRMS calculated for
C20H19ClFN2O3 389.1068, found: 389.1074.
1-Benzyl-3-nitro-4-(4-trifluoromethoxy)-phenyl)pyrrolidine, 6:
1
Yield: 87%, tRet = 4.40 min, m/z = 367.1 (M+H+). H NMR (600 MHz, CDCl3):
F3CO
NO2
/ppm 7.34-7.38 (6H, m), 7.28-7.32 (1H, m), 7.21 (2H, d, J = 7.8 Hz), 4.91 (1H, dt,
J = 4.8, 7.8 Hz), 4.04 (1H, dt, J = 6.6, 7.2 Hz), 3.76 (1H, d, J = 13.2 Hz), 3.72 (1H,
d, J = 13.2 Hz), 3.38 (1H, dd, J = 4.2, 10.8 Hz), 3.27 (1H, t, J = 8.4 Hz), 3.18 (1H,
N
Bn
dd, J = 7.8, 10.8 Hz), 2.72 (1H, dd, J = 6.6, 9.6 Hz); 13C NMR (150 MHz, CDCl3):
/ppm 148.5 (C), 139.6 (C), 137.7 (C), 128.9 (2CH), 128.6 (CH), 128.5 (2CH), 127.4 (2CH), 121.4
(2CH), 120.5 (CF3, q, J = 255 Hz), 90.9 (CH), 60.4 (CH2), 59.2 (CH2), 58.1 (CH2), 48.5 (CH). IR (neat) ν
= 2803.3 (w), 1549.6 (s), 1510.7 (m), 1454.7 (w), 1374.1 (w), 1341.3 (w), 1254.9 (s), 1215.2 (s), 1161.3

HETEROCYCLES, Vol. 82, No. 2, 2011
1307
(s), 1110.3 (m), 1019.6 (m), 849.8 (m), 735.3 (m), 699.7 (m) cm-1. HRMS calculated for C18H18F3N2O3
367.1270, found: 367.1277.
1-Benzyl-3-(4-methoxyphenyl)-4-nitropyrrolidine, 7:
Yield: 81%, tRet = 4.16 min, m/z = 313.2 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
7.25-7.37 (5H, m), 7.22 (2H, d, J = 8.4 Hz), 6.88 (2H, d, J = 8.4 Hz), 4.90 (1H, dt, J =
O
NO2
4.8, 7.2 Hz), 3.96 (1H, q, J = 6.6 Hz), 3.80 (3H, s), 3.72 (2H, app. q, J = 12.6 Hz),
3.40 (1H, dd, J = 3.6, 10.8 Hz), 3.27 (1H, t, J = 8.7 Hz), 3.09 (1H, dd, J = 7.8, 10.8
Hz), 2.66 (1H, dd, J = 7.5, 9.0 Hz); C NMR (150 MHz, CDCl3): /ppm 158.9 (C),
N
Bn
13
137.9 (C), 132.6 (C), 128.6 (2CH), 128.5 (2x2CH), 127.4 (CH), 114.3 (2CH), 91.4 (CH), 60.8 (CH2),
59.3 (CH2), 58.2 (CH2), 55.3 (CH3), 48.7 (CH). IR (neat) ν = 2916.4 (w), 2805.1 (w), 1611.7 (w), 1546.7
(s), 1513.9 (s), 1454.0 (m), 1372.6 (m), 1304.7 (m), 1248.7 (s), 1179.0 (s), 1030.7 (s), 829.7 (s), 733.7 (s),
700.2 (s) cm-1. HRMS calculated for C18H20N2O3 313.1552, found: 313.1549.
1-Benzyl-3(furan2-yl)-4-nitropyrrolidine, 8:
1
Yield: 91%, tRet = 3.77 min, m/z = 273.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
O2N
7.37 (1H, d, J = 1.2 Hz), 7.30-7.38 (4H, m), 7.29 (1H, app. sextet, J = 4.2 Hz), 6.33 (1H,
dd, J = 1.8, 3.0 Hz), 6.19 (1H, d, J = 3.0 Hz), 5.00 (1H, ddd, J = 3.6, 5.4, 7.8 Hz), 4.21
(1H, dt, J = 5.4, 8.4 Hz), 3.73 (1H, d, J = 13.2 Hz), 3.68 (1H, d, J = 13.2 Hz), 3.50 (1H,
O
N
Bn
dd, J = 3.0, 11.4 Hz), 3.30 (1H, t, J = 8.4 Hz), 2.96 (1H, dd, J = 7.2 , 11.4 Hz), 2.64 (1H, t, J = 8.4 Hz);
13C NMR (150 MHz, CDCl3): /ppm 152.5 (C), 142.3 (C), 137.7 (C), 128.6 (2CH), 128.5 (2CH), 127.4
(CH), 110.5 (CH), 106.6 (CH), 88.3 (CH), 59.0 (CH2), 57.8 (CH2), 57.7 (CH2), 42.6 (CH). IR (neat) ν =
2802.7 (w), 1548.1 (s), 1495.9 (m), 1454.4 (m), 1371.2 (m), 1327.6 (m), 1148.3 (m), 1074.3 (m), 1010.9
(m), 884.2 (w), 810.9 (w), 738.9 (s), 700.4 (m) cm-1. HRMS calculated for C15H17N2O3 273.1239, found:
273.1237.
1-Benzyl-3-methyl-3-nitro-4-phenylpyrrolidine, 9:
1
Yield: 88%, tRet = 4.26 min, m/z = 297.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
Bn
N
7.27-7.47 (m, 10 H), 4.27 (1H, t, J = 7.2 Hz), 3.77 (1H, d, J = 13.2 Hz), 3.74 (1H, d, J =
10.8 Hz), 3.72 (1H, d, J = 13.2 Hz), 3.27 (1H, t, J = 9.0 Hz), 2.90 (1H, dd, J = 7.9, 9.6 Hz),
13
2.69 (1H, d, J = 10.8 Hz), 1.25 (3H, s); C NMR (150 MHz, CDCl3): /ppm 138.0 (C),
130.0 (CH), 129.1 (2CH), 128.9 (CH), 128.5 (2x2CH), 128.4 (2CH), 127.4 (C), 96.2 (C),
O2N
64.7 (CH2), 59.5 (CH2), 58.9 (CH2), 51.2 (CH), 23.50 (CH3). IR (neat) ν = 2919.7 (w), 2801.3 (w), 1537.2
(s), 1495.4 (m), 1453.1 (m), 1388.3 (m), 1322.7 (s), 1110.9 (w), 1028.8 (w), 980.8 (w), 870.1 (m), 854.7
(m), 757.1 (m), 740.6 (m), 699.2 (s) cm-1. HRMS calculated for C18H21N2O2 297.1603, found: 297.1603.
1-Benzyl-3-(2-chlorophenyl)-4-nitropyrrolidine, 10:
1
Yield: 93%, tRet = 4.45 min, m/z = 317.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
NO2
7.43 (1H, d, J = 7.2 Hz), 7.38 (1H, d, J = 7.2 Hz), 7.32-7.36 (4H, m), 7.26-7.30 (2H, m),
7.21 (1H, t, J = 7.2 Hz), 5.03 (1H, dt, J = 4.2, 7.8 Hz), 4.52 (1H, dt, J = 4.8, 7.8 Hz), 3.76
Cl
N
Bn
(1H, d, J = 12.6 Hz), 3.72 (1H, d, J = 12.6 Hz), 3.23-3.33 (3H, m), 2.84 (1H, dd, J = 6.0,
9.6 Hz); 13C NMR (150 MHz, CDCl3): /ppm 138.1 (C), 137.9 (C), 133.9 (C), 129.9 (CH),
128.7 (CH), 128.6 (2CH), 128.5 (2CH), 128.4 (2CH), 127.4 (CH), 90.1 (CH), 59.3 (CH2), 59.2 (CH2),
58.5 (CH2), 45.9 (CH). IR (neat) ν = 2800.8 (w), 1670.8 (m), 1549.8 (s), 1495.3 (m), 1476.3 (m), 1453.7
(m), 1371.5 (m), 1131.1 (m), 1039.3 (m), 755.8 (s), 700.7 (s) cm-1. HRMS calculated for C17H18N2O2Cl
317.1057, found: 317.1057.

1308
HETEROCYCLES, Vol. 82, No. 2, 2011
Isopropyl-1-benzylpyrrolidine-3-carboxylate, 11:
Yield: 86%, tRet = 2.45 min, m/z = 248.2 (M+H+). H NMR (600 MHz, CDCl3): /ppm
7.22-7.35 (5H, m), 5.00 (1H, app. quin., J = 6.0 Hz), 3.65 (1H, d, J = 13.2 Hz), 3.61 (1H, d, J
= 13.2 Hz), 2.99 (1H, app. quin., J = 7.8 Hz), 2.91 (1H, t, J = 9.0 Hz), 2.70-2.75 (1H, m),
2.61 (1H, dd, J = 7.2, 9.0 Hz), 2.51 (1H, q, J = 8.4 Hz), 2.05-2.12 (2H, m), 1.23 (3H, d, J =
6.0 Hz), 1.22 (3H, d, J = 6.0 Hz); 13C NMR (150 MHz, CDCl3): /ppm 174.6 (C), 138.9 (C),
128.7 (2CH), 128.2 (2CH), 127.0 (CH), 67.7 (CH), 60.1 (CH2), 56.7 (CH2), 53.8 (CH2), 42.3
1
Bn
N
O
O
(CH), 27.6 (CH2), 21.8 (CH3), 21.7 (CH3). IR (neat) ν = 2978.1 (m), 2790.3 (m), 1727.8 (s), 1494.7 (m),
1453.4 (m), 1373.5 (m), 1193.9 (s), 1174.6 (s), 1108.6 (s), 911.1 (m), 855.9 (m), 739.5 (m), 699.7 (s) cm-1.
HRMS calculated for C15H22NO2Na 248.1645, found: 248.1643.
Diethyl-1-benzylpyrrolidin-3-ylphosphonate, 12:
1
Yield: 92%, tRet = 2.92 min, m/z = 298.3 (M+H+). H NMR (600 MHz, CDCl3): /ppm
Bn
7.25-7.36 (5H, m), 4.07-4.13 (4H, m), 3.63 (2H, s), 2.93-2.99 (1H, m), 2.80-2.84 (1H, m),
2.51-2.55 (2H, m), 2.42 (1H, q, J = 8.4 Hz), 2.04-2.09 (2H, m), 1.31 (6H, t, J = 6.6 Hz);
13C NMR (150 MHz, CDCl3): /ppm 138.8 (C), 128.7 (2CH), 128.2 (2CH), 127.0 (CH),
61.7 (2CH2, m), 59.9 (CH2), 54.2 (CH2), 53.8 (CH2, d, J = 6.3 Hz), 33.7 (CH, d, J = 148
N
O
P
OEt
EtO
Hz), 25.2 (CH2, d, J = 3.0 Hz), 16.4 (2CH3, m); 31P-NMR (162 MHz, CDCl3): /ppm 33.2 (s). IR (neat) ν
= 2978.7 (w), 2795.4 (w), 1670.4 (w), 1538.9 (w), 1495.2 (w), 1453.8 (w), 1391.0 (w), 1349.9 (w),
1231.4 (m), 1051.9 (s), 1021.6 (s), 956.9 (s), 850.2 (m), 788.4 (m), 741.8 (s), 698.7 (s) cm-1. HRMS
calculated for C15H25NO3P 298.1572, found: 298.1587.
1-Benzyl-3-(phenylsulfonyl)pyrrolidine, 13:
1
Yield: 83%, tRet = 2.55 min, m/z = 302.1 (M+H+). H NMR (600 MHz, CDCl3):
O
S
Bn
N
/ppm 7.89 (2H, d, J = 7.2 Hz), 7.66 (1H, t, J = 7.2 Hz), 7.56 (2H, t, J = 7.2 Hz),
7.28-7.32 (2H, m), 7.25-7.28 (3H, m), 3.76-3.79 (1H, m), 3.71 (1H, d, J = 12.6 Hz),
O
3.66 (1H, d, J = 12.6 Hz), 3.02 (1H, br. s), 2.91-2.96 (1H, m), 2.83 (1H, br. s), 2.64 (1H, q, J = 7.8 Hz),
2.30-2.34 (1H, m), 2.15 (1H, dt, J = 7.8, 17.4 Hz); 13C NMR (150 MHz, CDCl3): /ppm 138.3 (C), 133.8
(C), 129.3 (2CH), 128.8 (2CH), 128.5 (2CH), 128.4 (2CH), 127.6 (C+CH), 62.4 (CH), 59.4 (CH2), 53.4
(CH2), 53.2 (CH2), 25.8 (CH2). IR (neat) ν = 2800.2 (w), 1675.2 (w), 1446.6 (m), 1305.1 (s), 1290.0 (s),
1144.3 (s), 1085.7 (s), 921.7 (m), 732.1 (s), 689.4 (s) cm-1. HRMS calculated for C17H20NO2S 302.1215,
found: 302.1228.
4-(Benzo[d][1,3]dioxol-5-yl)-1-benzyl-3-methyl-3-nitropyrrolidine, 14:
1
Yield: 87%, tRet = 3.83 min, m/z = 341.1 (M+H+). H NMR (600 MHz, CDCl3):
Bn
O
N
/ppm 7.32-7.38 (4H, m), 7.27-7.29 (1H, m), 6.88 (1H, s), 6.74-6.80 (2H, m), 5.96
(2H, s), 4.16 (1H, t, J = 7.2 Hz), 3.74 (1H, d, J = 13.2 Hz), 3.67-3.73 (2H, m), 3.21
(1H, dd, J = 8.4 Hz), 2.83 (1H, dd, J = 7.2, 9.0 Hz), 2.67 (1H, d, J = 10.8 Hz), 1.27
(3H, s); 13C NMR (150 MHz, CDCl3): /ppm 147.8 (C), 146.9 (C), 138.1 (C), 131.6
O
O2N
(C), 128.5 (2CH), 128.4 (2CH), 127.3 (CH), 122.4 (CH), 109.2 (CH), 108.1 (CH), 101.1 (CH2), 96.3 (C),
64.5 (CH2), 59.5 (CH2), 59.1 (CH2), 51.6 (CH), 23.4 (CH3). IR (neat) ν = 2907.7 (w), 2804.0 (w), 1538.3
(s), 1504.3 (s), 1490.3 (s), 1444.6 (m), 1378.7 (w), 1344.3 (w), 1250.6 (m), 1237.0 (m), 1105.3 (w),
1038.5 (s), 933.9 (m), 858.9 (m), 811.1 (w), 739.3 (m), 700.1 (m) cm-1. HRMS calculated for C19H21N2O4
341.1501, found: 341.1510.
1-Benzyl-4-(2-chlorophenyl)pyrrolidine-3-amine, 15:
Yield: 95%, tRet = 3.67 min, m/z = 287.1 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
Cl
7.44 (1H, dd, J = 1.2, 7.8 Hz), 7.30-7.36 (5H, m), 7.22-7.26 (2H, m), 7.12 (1H, dt, J =
Bn
N
1.2, 7.8 Hz), 3.72 (1H, d, J = 12.6 Hz), 3.64 (1H, d, J = 12.6 Hz), 3.50-3.57 (2H, m),
3.12 (1H, dd, J = 6.6, 9.6 Hz), 3.08 (1H, dd, J = 8.1, 9.6 Hz), 2.70 (1H, dd, J = 5.4, 9.6
H2N

HETEROCYCLES, Vol. 82, No. 2, 2011
1309
Hz), 2.42-2.49 (3H, m); 13C NMR (150 MHz, CDCl3): /ppm 141.2 (C), 138.6 (C), 133.9 (C), 129.3 (CH),
128.8 (2CH), 128.3 (2CH), 128.2 (CH), 127.4 (CH), 127.3 (CH), 127.1 (CH), 62.9 (CH2), 60.3 (CH2),
60.1 (CH2), 59.8 (CH), 50.6 (CH). IR (neat) ν = 2909.9 (w), 2791.2 (m), 1671.9 (m), 1569.1 (m), 1494.9
(m), 1474.6 (m), 1453.0 (m), 1439.8 (m), 1377.8 (m), 1339.5 (m), 1259.4 (m), 1126.5 (m), 1034.1 (m),
858.8 (m), 751.2 (s), 699.2 (s) cm-1. HRMS calculated for C17H20N2Cl 287.1315, found: 287.1322.
1-Benzyl-4-(4-(trifluoromethoxy)phenyl)pyrrolidine-3-amine, 16:
1
Yield: 97%, tRet = 4.35 min, m/z = 337.1 (M+H+). H NMR (600 MHz, CDCl3):
F3CO
/ppm 7.29-7.36 (5H, m), 7.24-7.27 (2H, m), 7.14 (2H, d, J = 7.8 Hz), 3.70 (1H,
d, J = 13.2 Hz), 3.64 (1H, d, J = 13.2 Hz), 3.44 (1H, q, J = 6.6 Hz), 3.09 (1H, app.
Bn
N
t, J = 9.0 Hz), 3.02 (1H, dd, J = 7.8, 9.6 Hz), 2.93 (1H, q, J = 7.2 Hz), 2.64 (1H,
H2N
13
dd, J = 7.8, 9.0 Hz), 2.54 (1H, dd, J = 6.0, 9.6 Hz), 2.18 (2H, br. s); C NMR
(150 MHz, CDCl3): /ppm 147.8 (C), 142.3 (C), 138.7 (C), 128.7 (2x2CH), 128.3 (2CH), 127.0 (CH),
121.0 (2CH), 120.5 (CF3, q, J = 255 Hz) 63.5 (CH2), 61.3 (CH2), 60.3 (CH2), 60.2 (CH), 54.5 (CH). IR
(neat) ν = 2793.3 (w), 1508.7 (m), 1453.9 (w), 1254.5 (s), 1219.4 (s), 1156.3 (s), 1019.4 (m), 919.9 (m),
846.9 (m), 810.1 (m), 737.6 (m), 698.7 (s), 677.0 (m) cm-1. HRMS calculated for C18H20F3N2O 337.1528,
found: 337.1521.
1-Benzyl-4-(2-(benzyloxy)phenyl)pyrrolidin-3-amine, 17:
Yield: 93%, tRet = 3.54 min, m/z = 359.2 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
7.40-7.44 (4H, m), 7.18-7.38 (8H, m), 6.91 (1H, d, J = 7.8 Hz), 6.88 (1H, t, J = 7.8 Hz),
OBn
5.88 (2H, br. s), 5.06 (1H, d, J = 13.2 Hz), 5.04 (1H, d, J = 13.2 Hz), 3.83 (1H, br. s),
3.67 (1H, d, J = 13.2 Hz), 3.59 (1H, d, J = 13.2 Hz), 3.51-3.54 (1H, m), 3.27 (1H, t, J =
9.0 Hz), 3.01-3.05 (1H, m), 2.88-2.94 (2H, m); C NMR (150 MHz, CDCl3): /ppm
Bn
N
H2N
13
156.2 (C), 136.6 (C), 129.9 (CH), 129.5 (2CH), 129.0 (2CH), 128.7 (CH), 128.7 (2CH), 128.6 (CH),
128.4 (2CH), 128.3 (CH), 126.9 (2C), 121.6 (CH), 111.9 (CH), 70.4 (CH2), 59.4 (CH2), 58.9 (CH2), 57.0
(CH2), 56.3 (CH), 50.5 (CH). IR (neat) ν = 2700-3250 (br.), 1600.4 (m), 1585.6 (m), 1493.4 (m), 1451.8
(m), 1377.6 (m), 1237.3 (m), 1120.5 (m), 1007.9 (s), 911.6 (m), 853.8 (m), 748.7 (s), 734.4 (s), 697.3 (s)
cm-1. HRMS calculated for C24H27N2O 359.2123, found: 359.2118.
2-Benzyloctahydro-1H-isoindole-3a-amine, 18:
1
Yield: 97%, tRet = 0.41 min, m/z 231.2 (M+H+). H NMR (600 MHz, CDCl3): /ppm
NH2
7.33-7.28 (4H, m), 7.22 (1H, t, J = 6.6 Hz), 3.75 (1H, d, J = 13.2 Hz), 3.72 (1H, d, J =
N Bn
13.2 Hz), 3.01 (1H, dd, J = 7.8, 9.0 Hz), 2.75 (1H, s, J = 9.0 Hz), 2.51 (1H, dd, J = 5.4,
9.6 Hz), 2.47 (1H, d, J = 9.0 Hz), 1.75-1.83 (2H, m), 1.60-1.73 (3H, m), 1.48-1.55 (2H,
H
m), 1.37-1.45 (2H, m), 1.27-1.35 (2H, m); 13C NMR (150 MHz, CDCl3): /ppm 139.8 (C), 128.5 (2CH),
128.1 (2CH), 126.7 (CH), 65.4 (CH2), 61.0 (CH2), 57.8 (CH2), 57.7 (C), 45.9 (CH), 34.6 (CH2), 27.4
(CH2), 22.7 (CH2), 22.1 (CH2). IR (neat) ν = 2923.2 (m), 2854.1 (m), 2785.7 (m), 1602.7 (m), 1494.8 (m),
1451.2 (m), 1311.94 (w), 1214.1 (w), 1150.2 (m), 1071.9 (m), 1028.1 (m), 833.1 (m), 736.5 (s), 697.7 (s)
cm-1. HRMS calculated for C15H23N2 231.1861, found: 231.1858.
Octahydro-1H-isoindol-3a-amine, 19:
Yield: 90%, tRet = 0.41 min, m/z = 141.0 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm 3.25
NH2
(1H, dd, J = 7.2, 10.2 Hz), 2.99 (1H, d, J = 10.8 Hz), 2.78 (1H, dd, J = 4.8, 10.2 Hz), 2.59
NH
13
(1H, d, J = 10.8 Hz), 1.20-1.75 (12H, m); C NMR (150 MHz, CDCl3): /ppm 58.4 (C),
H
57.6 (CH2), 50.7 (CH2), 46.3 (CH), 34.4 (CH2), 27.0 (CH2), 23.2 (CH2), 22.7 (CH2). IR
(neat) ν = 3000-3400 (br.), 2925.3 (s), 2854.5 (m), 1655.7 (m), 1447.4 (m), 1259.4 (m), 1065.8 (m),
1019.1 (m), 795.6 (s), 729.2 (s), 700.2 (s) cm-1. HRMS calculated for C8H17N2 141.1388, found:
141.1386.

1310
HETEROCYCLES, Vol. 82, No. 2, 2011
4-(4-Methoxyphenyl)pyrrolidin-3-amine, 20:
1
Yield: 93%, tRet = 0.51 min, m/z = 193.1 (M+H+). H NMR (500 MHz, CDCl3):
O
/ppm 7.17 (2H, d, J = 8.7 Hz), 6.87 (2H, d, J = 8.7 Hz), 3.84 (3H, br. s), 3.78 (3H,
s), 3.60-3.42 (3H, m), 3.15 (1H, t, J = 15.0 Hz), 2.97-2.86 (2H, m); C NMR (125
13
NH
MHz, CDCl3): /ppm 158.9 (C), 130.6 (C), 128.5 (2CH), 114.4 (2CH), 59.2 (CH3),
55.3 (CH), 53.3 (CH), 52.3 (CH2), 51.3 (CH2). IR (neat) ν = 2800-3500 (br.), 2923.7
H2N
(m), 1610.3 (m), 1582.2 (m), 1512.8 (s), 1441.0 (m), 1247.0 (s), 1179.5 (s), 1111.7 (m), 1031.9 (s), 831.8
(m), 757.5 (m), 704.0 (m) cm-1. HRMS calculated for C11H17N2O 193.1341, found: 193.1347.
3-Methyl-4-phenylpyrrolidin-3-amine, 21:
1
Yield: 95%, tRet = 0.31 min, m/z = 177.1 (M+H+). H NMR (600 MHz, CDCl3): /ppm
7.35 (2H, t, J = 7.2 Hz), 7.29 (1H, t, J = 7.2 Hz), 7.24 (2H, d, J = 7.2 Hz), 4.12 (3 H, br. s),
3.75 (1H, dd, J = 8.4, 12.0 Hz), 3.54 (1H, dd, J = 8.4, 12.0 Hz), 3.22 (1H, t, J = 7.8 Hz),
3.17 (1H, d, J = 12.6 Hz), 3.13 (1H, d, J = 12.6 Hz), 0.95 (3H, s); C NMR (150 MHz,
NH
13
H2N
CDCl3): /ppm 137.2 (C), 128.6 (2CH), 128.1 (2CH), 127.5 (CH), 60.6 (C), 57.0 (CH2),
55.8 (CH), 48.8 (CH2), 23.3 (CH3). IR (neat) ν = 2900-3400 (br.), 1650.3 (m), 1555.4 (m), 1454.1 (m),
1403.6 (m), 1275.7 (m), 1260.9 (m), 764.6 (s), 750.1 (s), 702.8 (m) cm-1. HRMS calculated for C11H17N2
177.1392, found: 177.1398.
Methyl-5-(2-chloro-6-methoxyquinolin-3-yl)-3-nitro-4-phenylpyrrolidine-2-carboxylate, 22:
1
Yield: 32%, tRet = 4.76 min, m/z 442.2 (M+H+). H NMR (600 MHz, CDCl3):
/ppm 8.87 (1H, s), 7.94 (1H, d, J = 9.0 Hz), 7.41 (1H, dd, J = 3.0, 9.0 Hz),
7.30-7.33 (3H, m), 7.21 (1H, d, J = 3.0 Hz), 7.18 (2H, d, J = 7.2 Hz), 5.47 (1H, s),
O2N
5.16 (1H, d, J = 6.6 Hz), 4.95 (1H, d, J = 11.4 Hz), 3.96 (4H, m), 3.77 (3H, s); 13C
Cl
CO2Me
N
NMR (150 MHz, CDCl3): /ppm 173.2 (C), 158.5 (C), 146.0 (C), 143.3 (C), 137.6
N
H
(CH), 132.7 (C), 132.5 (C), 129.5 (CH), 129.0 (2CH), 128.7 (CH), 128.5 (C),
128.2 (2CH), 127.8 (CH), 105.6 (CH), 95.7 (CH), 62.8 (CH), 62.2 (CH), 55.7
(CH3), 52.6 (CH), 50.9 (CH3). IR (neat) ν = 1739.6 (m), 1622.2 (m), 1591.5 (s),
OMe
1548.9 (s), 1497.2 (s), 1348.2 (m), 1227.9 (s), 1162.0 (m), 1047.3 (m), 832.2 (m),
736.5 (m), 698.7 (m) cm-1. HRMS calculated for C22H21N3O5Cl 442.1170, found: 442.1188; X-ray data:
CCDC 782326; space group Pbca; Unit cell parameters: a = 19.6970(2) Å, b = 9.3719(1) Å, c =
22.1754(3) Å, α = 90 °, β = 90 °, γ = 90 °.
Methyl-2-nitro-3-(thiophen-2-yl)-1-(4-(trifluoromethyl)phenyl)hexahydro-1H-pyrrolizine-7a-carbo-
xylate, 23:
Yield: 79%, tRet = 5.18 min, m/z 441.1 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
F3C
OMe
O
7.59 (2H, d, J = 7.8 Hz), 7.32-7.38 (3H, m), 7.05 (1H, d, J = 2.4 Hz), 7.02 (1H, t, J =
4.2 Hz), 6.38 (1H, dd, J = 7.8, 11.4 Hz), 5.61 (1H, d, J = 7.8 Hz), 4.42 (1H, d, J =
11.4 Hz), 3.38 (3H, s), 2.94 (1H, dt, J = 7.8, 9.0 Hz), 2.76-2.81 (2H, m), 2.15-2.19
(1H, m), 2.01-2.07 (1H, m), 1.90-2.00 (1H, m); 13C NMR (150 MHz, CDCl3): /ppm
173.4 (C), 138.2 (C), 137.3 (C), 130.3 (C, q, J = 34 Hz), 129.8 (CH), 128.3 (C, q, J =
267 Hz), 127.6 (2CH), 127.1 (CH), 127.0 (CH), 125.7 (2CH, q, J = 3 Hz), 90.9 (CH),
N
O2N
S
79.8 (C), 61.9 (CH), 53.1 (CH), 52.0 (CH3), 46.1 (CH2), 34.8 (CH2), 27.6 (CH2). IR (neat) ν = 1731.8 (m),
1621.4 (w), 1549.2 (s), 1433.8 (w), 1371.5 (w), 1324.6 (s), 1165.1 (s), 1118.0 (s), 1067.1 (s), 1017.6 (m),
910.1 (m), 838.3 (m), 728.2 (m), 705.3 (s) cm-1. HRMS calculated for C20H20N2O4F3S 441.1096, found:
441.1075; X-ray data: CCDC 782329; space group P2(1)/n; Unit cell parameters: a = 12.3233(2) Å, b =
13.7686(2) Å, c = 14.1185(2) Å, α = 90 °, β = 114.309(1) °, γ = 90 °.

HETEROCYCLES, Vol. 82, No. 2, 2011
1311
Methyl-1-(3-chlorophenyl)-3-cyclohexyl-2-nitrohexahydro-1H-pyrrolizine-7a-carboxylate, 24:
Yield: 89%, tRet = 5.07 min, m/z 407.2 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
7.20-7.25 (2H, m), 7.10 (1H, s), 6.99 (1H, d, J = 6.6 Hz), 4.17 (1H, dd, J = 7.2, 10.8
Hz), 3.83 (1H, d, J = 6.0 Hz), 3.44 (1H, dd, J = 7.8, 14.4 Hz), 3.25 (3H, s), 3.15 (1H,
dd, J = 7.8, 15.6 Hz), 2.40-2.50 (1H, m), 2.19-2.28 (2H, m), 2.09 (1H, d, J = 12.0 Hz),
OMe
O
Cl
N
O2N
13
1.88-1.93 (1H, m), 1.63-1.72 (6H, m), 1.21-1.35 (4H, m), 1.11 (1H, m); C NMR
(150 MHz, CDCl3): /ppm 172.4 (C), 138.6 (C), 134.6 (C), 129.9 (CH), 128.0 (CH),
127.7 (CH), 125.8 (CH), 98.0 (CH), 83.4 (C), 73.1 (CH), 63.3 (CH), 51.5 (CH3), 47.0 (CH2), 37.3 (CH),
34.0 (CH2), 32.2 (CH2), 30.9 (CH2), 26.3 (CH2), 25.7 (CH2), 25.5 (CH2), 22.7 (CH2), . IR (neat) ν =
2925.7 (m), 2853.4 (m), 1732.9 (s), 1545.2 (s), 1449.6 (m), 1432.9 (m), 1336.0 (m), 1281.6 (m), 1227.6
(m), 1194.8 (m), 1152.1 (m), 1114.1 (m), 1082.9 (m), 1061.8 (m), 781.7 (m), 729.8 (m), 694.0 (s) cm-1.
HRMS calculated for C21H27N2O4Cl 407.1738, found: 407.1750.
Methyl-2-nitro-3-(thiophen-2-yl)-1-(4-methoxyphenyl)hexahydro-1H-pyrrolizine-7a-carboxylate,
25:
Yield: 76%, tRet = 5.18 min, m/z 441.1 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm
MeO
OMe
7.33 (1H, d, J = 4.8 Hz), 7.13 (2H, d, J = 8.4 Hz), 7.03 (1H, d, J = 3.0 Hz), 6.99 (1H,
t, J = 4.2 Hz), 6.84 (2H, d, J = 8.4 Hz), 6.31 (1H, dd, J = 8.4, 12.0 Hz), 5.60 (1H, d,
J = 7.8 Hz), 4.31 (1H, d, J = 11.4 Hz), 3.77 (3H, s), 3.40 (3H, s), 2.92 (1H, dt, J =
7.2, 9.0 Hz), 2.72-2.80 (2H, m), 2.10-2.17 (1H, m), 1.95-2.00 (1H, m), 1.86-1.93
(1H, m); 13C NMR (150 MHz, CDCl3): /ppm 173.9 (C), 159.3 (C), 137.7 (C),
129.6 (CH), 128.2 (2CH), 127.0 (CH), 126.9 (CH), 125.8 (C), 114.2 (2CH), 91.3
O
N
O2N
S
(CH), 80.0 (C), 62.0 (CH), 55.2 (CH3), 52.8 (CH), 52.0 (CH3), 46.3 (CH2), 34.8 (CH2), 27.6 (CH2). IR
(neat) ν = 2952.2 (w), 1730.2 (m), 1612.4 (w), 1547.5 (s), 1514.4 (s), 1441.1 (m), 1370.5 (m), 1303.7 (m),
1250.6 (s), 1179.3 (s), 1120.4 (m), 1030.6 (s), 834.9 (s) 703.6 (s) cm-1. HRMS calculated for
C20H23N2O5S 441.1096, found: 441.1075.
Methyl-1-(furan-2-yl)-3-isopropyl-2-nitrohexahydro-1H-pyrrolizine-7a-carboxylate, 26:
Yield: 82%, tRet = 4.47 min, m/z 323.2 (M+H+). 1H NMR (600 MHz, CDCl3): /ppm 7.32
(1H, s), 6.31 (1H, s), 6.18 (1H, d, J = 3.0 Hz), 5.48 (1H, t, J = 6.6 Hz), 3.97-4.05 (2H, m),
OMe
O
O
3.45 (3H, s), 3.39-3.44 (1H, m), 3.18 (1H, q, J = 7.8 Hz), 2.52 (1H, dt, J = 8.4, 13.2 Hz),
2.33 (1H, ddd, J = 5.4, 8.4, 13.2 Hz), 2.15-2.23 (1H, m), 1.92-2.05 (2H, m), 1.20 (3H, d, J
N
O2N
= 6.0 Hz), 1.03 (3H, d, J = 6.0 Hz); 13C NMR (150 MHz, CDCl3): /ppm 172.1 (C), 149.9
(C), 142.4 (CH), 110.6 (CH), 107.5 (CH), 96.2 (CH), 81.4 (C), 73.9 (CH), 56.0 (CH), 52.2
(CH3), 46.9 (CH2), 33.8 (CH2), 27.8 (CH), 22.7 (CH2), 22.3 (CH3), 20.7 (CH3). IR (neat) ν = 2953.8 (w),
2877.6 (w), 1736.5 (s), 1547.9 (s), 1370.7 (m), 1336.5 (m), 1233.1 (m), 1148.7 (m), 1080.9 (m), 1066.9
(m), 1012.4 (m), 913.4 (m), 735.7 (s) cm-1. HRMS calculated for C16H23N2O5 323.1607, found: 323.1603;
X-ray data: CCDC 782330; space group P2(1)/c; Unit cell parameters: a = 7.83550(1) Å, b = 12.8006(2)
Å, c = 17.5169(3) Å, α = 90 °, β = 99.445(1) °, γ = 90 °.
Methyl 1-(4-fluorophenyl)-2-nitrohexahydro-1H-pyrrolizine-7a-carboxylate, 27:
1
F
Yield: 78%, tRet = 4.36 min, m/z 309.2 (M+H+). H NMR (600 MHz, CDCl3): /ppm
7.24 (2H, dd, J = 5.4, 8.4 Hz), 6.97 (2H, app. t, J = 9.0 Hz), 5.73 (1H, d, J = 10.2 Hz),
4.00 (1H, dt, J = 7.2, 10.8 Hz), 3.79 (3H, s), 3.27-3.30 (1H, m), 3.24 (1H, t, J = 12.6
Hz), 3.17 (1H, dd, J = 7.2, 12.6 Hz), 2.72-2.78 (1H, m), 2.32 (1H, dd, J = 6.0, 12.6 Hz),
1.76-1.97 (2H, m), 1.55 (1H, dt, J = 7.2, 12.6 Hz); 13C NMR (150 MHz, CDCl3):
OMe
O
N
O2N
/ppm 173.3 (C), 162.1 (C, d, J = 240 Hz), 132.1 (C), 129.1 (2CH, d, J = 8 Hz), 115.7 (2CH, d, J = 14
Hz), 96.0 (CH), 77.8 (C), 58.4 (CH2), 56.9 (CH2), 53.2 (CH3), 42.3 (CH), 32.0 (CH2), 26.2 (CH2). IR
(neat) ν = 2956.1 (w), 2876.5 (w), 1731.9 (s), 1606.2 (w), 1546.1 (s), 1511.6 (s), 1369.9 (m), 1272.6 (m),
1224.3 (s), 1161.7 (s), 1013.7 (m), 835.7 (s), 718.6 (m) cm-1. HRMS calculated for C15H18N2O4F,

1312
HETEROCYCLES, Vol. 82, No. 2, 2011
309.1239 found: 309.1243.
Methyl-1-(benzo[d][1,3]dioxol-5-yl)-2-methyl-2-nitrohexahydro-1H-pyrrolizine-7a-carboxylate, 28:
1
Yield: 83%, tRet = 3.95 min, m/z 349.1 (M+H+). Diastereoisomer 1: H NMR (600
O
OMe
O
MHz, CDCl3): /ppm 6.72-6.75 (2H, m), 6.69 (1H, d, J = 8.4 Hz), 5.93 (2H, d, J = 3.6
Hz), 4.11 (1H, dd, J = 7.8, 10.8 Hz), 3.81 (3H, s), 3.66 (1H, d, J = 4.2 Hz), 3.64 (1H,
d, J = 7.2 Hz), 3.27 (1H, t, J = 7.2 Hz), 3.00 (1H, ddd, J = 5.4, 7.8, 10.8 Hz), 2.65 (1H,
dd, J = 7.2, 13.2 Hz), 2.03-2.10 (1H, m), 1.88-1.98 (1H, m), 1.48 (3H, s), 1.45-1.49
O
N
O2N
13
(1H, m); C NMR (150 MHz, CDCl3): /ppm 174.0 (C), 147.9 (C), 147.6 (C), 126.7 (C), 122.8 (CH),
109.2 (CH), 108.3 (CH), 101.2 (CH2), 97.9 (C), 86.0 (C), 57.6 (CH2), 57.3 (CH), 55.1 (CH2), 53.1 (CH3),
31.0 (CH2), 28.4 (CH2), 19.4 (CH3). Diastereoisomer 2: 1H NMR (600 MHz, CDCl3): /ppm 6.73 (1H, d,
J = 8.4 Hz), 6.71 (1H, s), 6.67 (1H, d, J = 8.4 Hz), 5.92 (2H, d, J = 4.8 Hz), 4.40 (1H, dd, J = 7.8, 12.0
Hz), 3.79 (3H, s), 3.59 (1H, t, J = 12.0 Hz), 3.42 (1H, t, J = 7.8 Hz), 3.10 (1H, dd, J = 7.8, 12.0 Hz), 2.81
(1H, ddd, J = 5.4, 9.6, 15.0 Hz), 2.37 (1H, dd, J = 6.0, 12.6 Hz), 1.95-2.02 (1H, m), 1.91-1.94 (1H, m),
13
1.84-1.88 (1H, m), 1.63 (1H, ddd, J = 5.4, 11.4, 16.8 Hz), 1.39 (3H, s); C NMR (150 MHz, CDCl3):
/ppm 173.0 (C), 147.8 (C), 147.2 (C), 127.5 (C), 122.2 (CH), 109.1 (CH), 108.3 (CH), 101.1 (CH2), 98.8
(C), 83.1 (C), 57.6 (CH2), 56.3 (CH2), 52.6 (CH3), 47.6 (CH), 34.9 (CH2), 25.2 (CH2), 18.6 (CH3). IR
(neat) ν = 2949.9 (w), 2874.6 (w), 1729.9 (s), 1539.6 (s), 1504.9 (m), 1488.3 (s), 1442.7 (s), 1390.4 (m),
1350.0 (w), 1306.1 (w), 1255.8 (s), 1234.3 (s), 1167.6 (s), 1036.2 (s), 930.9 (s), 864.9 (m), 814.7 (m),
731.4 (m) cm-1. HRMS calculated for C17H21N2O6, 349.1400 found: 349.1384.
Methyl-5-(2-fluorophenyl)-3-phenyl-1H-pyrrole-2-carboxylate, 29:
1
Yield: 22%, tRet = 5.06 min, m/z = 318.2 (M+Na+). H NMR (600 MHz, CDCl3):
Ph
/ppm 9.73 (1H, br. s), 7.67 (1H, ddd, J = 1.3, 7.8, 7.8 Hz), 7.62-7.60 (2H, m), 7.41
H
O
F
(2H, pt, J = 7.6 Hz), 7.34 (1H, pt, J = 7.4 Hz), 7.29 (1H, dd, J = 13.2, 6.0 Hz),
7.23-7.16 (2H, m), 6.75 (1H, d, J = 2.9 Hz), 3.82 (3H, s); 13C NMR (150 MHz,
CDCl3): /ppm 161.3 (C), 159.3 (C, d, J = 247 Hz), 134.9 (C), 133.0 (C), 130.2 (C, d,
J = 2 Hz), 129.6 (2CH), 129.2 (CH, d, J = 9 Hz), 128.0 (2CH), 127.5 (CH, d, J = 4
N
O
H
Hz), 127.3 (CH), 125.0 (CH, d, J = 3 Hz), 118.8 (C, d, J = 11 Hz), 118.6 (C, d, J = 2 Hz), 116.7 (CH, d, J
= 23 Hz), 111.6 (CH, d, J = 2 Hz), 51.6 (CH3). IR (neat) ν = 3462 (bw), 3287 (bw), 2985 (m), 1715 (s),
1687 (s), 1492 (m), 1471 (s), 1453 (s), 1234 (s), 1124 (m), 1107 (m), 1067 (m), 1009 (m), 946 (w), 817
(m), 761 (s), 698 (m) cm-1. HRMS calculated for C18H15NO2F+ 296.1081, found: 296.1070.
Methy-5-(2-fluorophenyl)-4-nitro-3-phenyl-1H-pyrrole-2-carboxylate, 30:
Yield: 20%, tRet = 4.78 min, m/z = 339.1 (M-H+). H NMR (600 MHz, CDCl3):
1
Ph
O2N
F
/ppm 10.21 (1H, br. s), 7.54 (1H, t, J = 7.3 Hz), 7.49-7.45 (1H, m), 7.41-7.36 (5H,
O
13
m), 7.26 (1H, dd, J = 6.9, 8.1 Hz), 7.20 (1H, t, J = 9.2 Hz), 3.54 (3H, s); C NMR
N
O
(150 MHz, CDCl3): /ppm 161.3 (C), 160.1 (C, d, J = 251 Hz), 134.6 (C), 132.1 (CH,
d, J = 9 Hz), 131.0 (C), 130.9 (CH), 129.9 (2CH), 128.6 (C), 128. (CH), 127.8
(2CH), 127.4 (C), 124.5 (CH, d, J = 4 Hz), 119.1 (C), 117.2 (C, d, J = 14 Hz), 116.3
H
(CH, d, J = 22 Hz), 52.2 (CH3). IR (neat) ν = 3258 (w), 2955 (w), 1677 (s), 1621 (w), 1584 (w), 1560 (w),
1496 (s), 1449 (s), 1409 (m), 1365 (m), 1338 (m), 1298 (s), 1279 (s), 1236 (m), 1206 (m), 1168 (w), 1104
(w), 1033 (w), 945 (s), 912 (w), 859 (m), 814 (m), 757 (s), 738 (s), 697 (s) cm-1. HRMS calculated for
C18H14N2O4F+ 341.0938 found: 341.0936. X-ray data: CCDC782327; space group P2(1)/n; Unit cell
parameters: a = 14.1489 Å, b = 11.6603 Å, c = 19.3413 Å, α = 90°, β = 100.28°, γ = 90°.

HETEROCYCLES, Vol. 82, No. 2, 2011
1313
Methyl-5-(2-chloro-6-methoxyquinolin-3-yl)-3-phenyl-1H-pyrrole-2-carboxylate, 31:
1
Yield: 20%, tRet = 5.30 min, m/z = 393.1 (M+H+). H NMR (600 MHz,
CDCl3): /ppm 9.91 (1H, br. s), 8.25 (1H, s), 7.92 (1H, d, J = 9.2 Hz), 7.62
(2H, d, J = 7.2 Hz), 7.43-7.40 (2H, m), 7.39 (1H, dd, J = 2.7, 9.2 Hz),
7.37-7.35 (1H, m), 7.08 (1H, d, J = 2.7 Hz), 6.01 (1H, d, J = 3.1 Hz), 3.94
(3H, s), 3.82 (3H, s); 13C NMR (150 MHz, CDCl3): /ppm 161.2 (C),
Ph
H
O
O
N
O
H
Cl
N
158.7 (C), 144.2 (C), 142.7 (C), 136.3 (CH), 134.5 (C), 132.8 (C), 130.4 (C), 129.7 (CH), 129.4 (2CH),
128.2 (C), 127.9 (2CH), 127.3 (CH), 124.4 (C), 123.8 (CH), 119.1 (C), 114.0 (CH), 104.8 (CH), 55.6
(CH3), 51.6 (CH3); IR (neat) ν = 3292 (m), 2949 (w), 1662 (s), 1621 (m), 1604 (w), 1562 (w), 1496 (m),
1480 (m), 1455 (m), 1364 (w), 1346 (s), 1279 (s), 1206 (m), 1165 (m), 1138 (m), 1036 (s), 1006 (w), 957
(w), 909 (w), 827 (m), 809 (m), 763 (s), 699 (s) cm-1. HRMS calculated for C22H18N2O3Cl+ 393.1006,
found: 393.1005.
Methyl-5-(2-chloro-6-methoxyquinolin-3-yl)-4-nitro-3-phenyl-1H-pyrrole-2-carboxylate, 32:
Yield: 24%, tRet = 5.07 min, m/z = 438.1 (M+H+). H NMR (600 MHz,
1
Ph
O2N
CDCl3): /ppm 10.31 (1H, br. s), 8.16 (1H, s), 7.94 (1H, d, J = 9.2 Hz),
O
7.46-7.38 (6H, m), 7.03 (1H, d, J = 2.3 Hz), 3.93 (3H, s), 3.53 (3H, s);
13C NMR (150 MHz, CDCl3): /ppm 160.9 (C), 158.7 (C), 146.2 (C),
143.7 (C), 139.2 (CH), 134.6 (C), 130.6 (C), 130.1 (C), 129.9 (2CH),
129.8 (CH), 128.2 (CH), 127.7 (2CH), 127.2 (CH), 127.1 (C), 124.7
N
O
O
H
Cl
N
(CH), 123.0 (C); 119.3 (C), 105.3 (CH), 55.7 (CH3), 52.1 (CH3); IR (neat) ν = 3676 (w), 2988 (s), 2901
(s), 1705 (w), 1620 (w), 1495 (m), 1451 (m), 1404 (m), 1354 (m), 1275 (m), 1228 (s), 1159 (w), 1079 (s),
1066 (s), 907 (w), 834 (m), 725 (m), 696 (m) cm-1. HRMS calculated for C22H17N3O5Cl+ 438.0857,
found: 438.0855. X-ray data: CCDC 782328; space group P-1; Unit cell parameters: a = 9.5144 Å, b =
9.6002 Å, c = 12.5135 Å, α = 75.501°, β = 86.354°, γ = 75.572°.
Methyl 5-(4-bromophenyl)-4-nitro-3-phenyl-1H-pyrrole-2-carboxylate, 33:
1
Yield: 40%, tRet = 5.15 min, m/z = 423.0 (M+Na+). H NMR (400 MHz,
Ph
CDCl3): /ppm 9.79 (1H, br. s), 7.62 (2H, d, J = 8.5 Hz), 7.48 (2H, d, J = 8.5
Hz), 7.42-7.40 (3H, m), 7.36-7.34 (2H, m), 3.61 (3H, s); 13C NMR (100 MHz,
CDCl3): /ppm 161.2 (C), 133.5 (C), 132.1 (2CH), 131.0 (C), 130.7 (2CH),
129.8 (2CH), 128.3 (CH), 127.9 (2CH), 127.8 (C), 127.7 (C), 124.8 (C), 118.8
(C), 52.2 (CH3); IR (neat) ν = 3355 (w), 3314 (w), 3171 (w), 2924 (w), 1708
(m), 1683 (s), 1658 (s), 1619 (s), 1563 (m), 1492 (s), 1449 (m), 1384 (m), 1358
O2N
O
O
N
H
Br
(s), 1197 (m), 1101 (m), 1068 (s), 1010 (s), 951 (w), 843 (m), 831 (m), 765 (s), 699 (s) cm-1. HRMS
calculated for C18H14N2O4Br 401.0137, found: 401.0152.
Methyl 5-cyclohexyl-3-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate, 34:
Yield: 21%, tRet = 5.20 min, m/z = 314.2 (M+H+). H NMR (600 MHz, CDCl3):
/ppm 8.84 (1H, br. s), 7.50 (2H, d, J = 8.5 Hz), 6.91 (2H, d, J = 8.5 Hz), 6.05 (1H,
1
O
d, J = 2.7 Hz), 3.84 (3H, s), 3.76 (3H, s), 2.61-2.58 (1H, m), 2.03 (2H, d, J = 11.3
Hz), 1.84 (2H, d, J = 12.3 Hz), 1.74 (1H, d, J = 12.2 Hz), 1.46-1.35 (4H, m),
1.29-1.23 (1H, m); 13C NMR (150 MHz, CDCl3): /ppm 161.5 (C), 158.7 (C),
142.5 (C), 132.5 (C), 130.4 (2CH), 127.9 (C), 115.4 (C), 113.2 (2CH), 108.3 (CH),
55.2 (CH3), 51.0 (CH3), 36.8 (CH), 32.7 (2CH2), 26.1 (2CH2), 25.9 (CH2). IR (neat)
H
O
N
O
H
ν = 3307 (w), 2926 (m), 2851 (w), 1664 (s), 1611 (w), 1523 (s), 1449 (s), 1364 (w),
1246 (s), 1177 (s); 1100 (m), 908 (m), 835 (m), 806 (m), 731 (s) cm-1. HRMS
calculated for C19H24NO3 314.1756, found: 314.1758.

1314
HETEROCYCLES, Vol. 82, No. 2, 2011
Methyl 5-cyclohexyl-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-carboxylate, 35:
Yield: 10%, tRet = 5.05 min, m/z = 381.19 (M+Na+). H NMR (600 MHz, CDCl3):
/ppm 9.09 (1H, br. s). 7.23 (2H, d, J = 8.6 Hz), 6.92 (2H, d, J = 8.6 Hz), 3.85 (3H,
1
O
s), 3.69 (3H, s), 3.47 (1H, tt, J = 2.84, 11.7 Hz), 2.11 (2H, d, J = 11.7 Hz), 1.90 (2H,
d, J = 13.1 Hz), 1.82 (1H, d, J = 13.1 Hz), 1.52-1.46 (2H, m), 1.41 (2H, ddd, J =
2.4, 12.1, 15.2 Hz), 1.27-1.25 (1H, m); 13C NMR (150 MHz, CDCl3): /ppm 160.9
(C), 159.2 (C), 142.7 (C), 131.0 (2CH), 127.3 (C), 123.4 (C), 116.9 (C), 113.1
(2CH), 55.2 (CH3), 51.9 (CH3), 36.1 (CH), 31.6 (2CH2), 26.1 (2CH2), 25.8 (CH2).
O2N
O
N
O
H
IR (neat) ν = 3295 (w), 2930 (m), 2854 (w), 1695 (s), 1613 (w), 1528 (m), 1493 (s),
1446 (s), 1358 (s), 1245 (s), 1176 (m), 1096 (w), 1034 (m), 909 (m), 846 (m), 830
(m), 782 (m), 729 (s) cm-1. HRMS calculated for C19H23N2O5 359.1607, found: 359.1617.
ACKNOWLEDGEMENTS
We gratefully acknowledge financial support from the Cambridge European Trust and Ralph Raphael
Studentship (to MB), the Royal Society (to IRB), the Fonds der Chemischen Industrie (to JW) and the
BP1702 endowment (to SVL). Furthermore, we wish to thank Dr J. Davies for determining the X-ray
structures of compounds 22, 23, 26, 30 and 32 and the EPSRC towards the purchase of the X-ray
diffractometer.
REFERENCES (AND NOTES)
1. M. Congreve, C. W. Murray, and T. L. Blundell, Drug Discovery Today, 2005, 10, 895; J. P.
Kennedy, L. Williams, T. M. Bridges, R. N. Daniels, D. Weaver, and C. W. Lindsley, J. Comb.
Chem., 2008, 10, 345; C. W. Murray and D. C. Rees, Nature Chem., 2009, 1, 187; I. Tickle, A. Sharff,
M. Vinkovic, J. Yon, and H. Jhoti, Chem. Soc. Rev., 2004, 33, 558.
2. M. Baumann, I. R. Baxendale, N. Nikbin, and S. V. Ley, manuscript in preparation.
3. Y. Kumar, M. Prasad, K. Singh, and S. K. Dhingra, PCT Int. Appl. WO2005023763.
4. S. Winter, J. Bosch, J. Puig Serrano, and J. J. Soto, U.S. Pat. Appl. US 2008167479.
5. P. R. Verhoest and C. Proulx-LaFrance, PCT Int. Appl. WO2008139293.
6. J.-M. Adam, P. Dott, H. Iding, H.-J. Mair, R. Reents, snd B. Wirz, PCT Int. Appl. WO2008077797.
7. A. B. Feurer, S. Bennabi, H. Heckroth, J. Ergüden, T. Schenke, M. Bauser, R. Kast, J.-P. Stasch, E.
Stahl, K. Münter, D. Lang, and H. Ehmke, PCT Int. Appl. WO2003106450.
8. I. S. Mitchell, J. F. Blake, R. Xu, N. C. Kallan, D. Xiao, K. L. Spencer, J. Bencsik, J. Liang, B.
Safina, J. Li, and C. Chabot, PCT Int. Appl. 2008006032.
9. J. A. Leonard, J. M. Miller, PCT Int. Appl. WO2007057755.
10. C. M. Baum, PCT Int. Appl. WO2006120557.
11. M. Baumann, I. R. Baxendale, and S. V. Ley, Synlett, 2010, 749; M. Grafton, A. C. Mansfield, and M.
J. Fray, Tetrahedron Lett., 2010, 51, 1026.

HETEROCYCLES, Vol. 82, No. 2, 2011
1315
12. F. Trachsel and P. R. von Rohr, ‘Heat transfer in homogeneous systems’ Vol. 1, ed. by V. Hessel,
Wiley-VCH Verlag, GmbH&Co. KGaA, Weinheim, Germany, 2009, pp. 255-281; D. Ziegenbalg, P.
Löb, A. Al-Rawashdeh, D. Kralisch, and V. Hessel, Chem. Engineering Science, 2010, 65, 3557.
13. M. Baumann, I. R. Baxendale, and S. V. Ley, Synlett, 2008, 14, 2111; A. A. Kulkami, V. S. Kalyani,
R. A. Joshi, and R. R. Joshi, Org. Proc. Res. Dev., 2009, 13, 999; M. Baumann, I. R. Baxendale, S. V.
Ley, N. Nikbin, C. D. Smith, and J. P. Tierney, Org. Biomol. Chem., 2008, 6, 1577; B. Ahmed-Omer,
D. A. Barrow, and T. Wirth, Tetrahedron Lett., 2009, 50, 3352; L. Malet-Sanz, J. Madrzak, R. S.
Holvey, and T. Underwood, Tetrahedron Lett., 2009, 50, 7263; M. Baumann, I. R. Baxendale, S. V.
Ley, N. Nikbin, and C. D. Smith, Org. Biomol. Chem., 2008, 6, 1587; S. Hübner, U. Bentrup, U.
Budde, K. Lovis, T. Diedrich, A. Freitag, L. Küpper, and K. Jähnisch, Org. Proc. Res. Dev., 2009, 13,
952; J. C. Brandt and T. With, Beilstein J. Org. Chem., 2009, 5, no. 30; M. O’Brien, I. R. Baxendale,
and S. V. Ley, Org. Lett., 2010, 12, 1596.
14. V. Hessel, P. Loeb, and H. Loewe, ‘Industrial microreactor process development up to production’ ed.
by V. Hessel, Wiley-VCH Verlag, GmbH&Co. KGaA, Weinheim, Germany, 2009, pp. 183-247; M.
Baumann, I. R. Baxendale, S. V. Ley, C. D. Smith, and G. K. Tranmer, Org. Lett., 2006, 8, 5231; F.
Venturoni, N. Nikbin, S. V. Ley, and I. R. Baxendale, Org. Biomol. Chem., 2010, 8, 1798; C. H.
Hornung, M. R. Mackley, I. R. Baxendale, and S. V. Ley, Org. Proc. Res. Dev., 2007, 11, 399.
15. I. R. Baxendale, S. V. Ley, A. C. Mansfield, and C. D. Smith, Angew. Chem., Int. Ed., 2009, 48,
4017; A. Kirschning and G. Jas, ‘Applications of immobilized catalysts in continuous flow
processes’ in Topics in Current Chemistry, 2004, Springer Berlin, Heidelberg, pp. 209-239; K.
Mennecke and A. Kirschning, Synthesis, 2008, 20, 3267; M. D. Hopkin, I. R. Baxendale, and S.V.
Ley, Chem. Comm., 2010, 46, 2450; G. Jas and A. Kirschning, Chem. Eur. J., 2003, 9, 5708; J.
Kobayashi, Y. Mori, and S. Kobayashi, Chem. Asian J., 2006, 1, 22; B. Brandtand and T. Wirth, Org.
Biomol. Chem., 2007, 5, 733; T. Fukuyama, M. T. Rahman, M. Sato, and I. Ryu, Synlett, 2008, 151; J.
Yoshida, A. Nagaki, and T. Yamada, Chem. Eur. J., 2008, 14, 7450.
16. Vapourtec R2+/R4 units are available from Vapourtec Ltd, Park Farm Buisness Centre, Fornham St
Genevieve, Bury St. Edmunds, Suffolk, IP28 6TS, UK. Website: http://www.vapourtec.co.uk.
17. Quadrapure high loading resins are commercially available from Reaxa. Website:
http://www.reaxa.com.
18. M. Baumann, I. R. Baxendale, L. J. Martin, and S. V. Ley, Tetrahedron, 2009, 65, 6611.
19. The H-Cube® flow hydrogenator is commercially available from ThalesNano Nanotechnology Inc.,
Graphisoft Park, H-1031 Budapest, Záhony u. 7, Hungary. Website: http://www.thalesnano.com.
20. R. Martin, S. V. Ley, I. R. Baxendale, and M. Baumann, unpublished results.
21. G. Galley, J. Liebscher, and M. Pätzel, J. Org. Chem., 1995, 60, 5005; M. Ayerbe, A. Arrieta, and F.

1316
HETEROCYCLES, Vol. 82, No. 2, 2011
P. Cossio, J. Org. Chem., 1998, 63, 1795.
22. J. S. Carey, J. Org. Chem., 2001, 66, 2526; P. L. Kotian, T.-H. Lin, Y. El Kattan, and P. Chand, Org.
Proc. Res. Dev., 2005, 9, 193.
23. C. Chen, X. Li, and S. L. Schreiber, J. Am. Chem. Soc., 2003, 125, 10174.
24. R. Robles-Machín, M. González-Esguevillas, J. Adrio, and J. C. Carretero, J. Org. Chem., 2010, 75,
233.
25. B. M. Trost and S. M. Silverman, J. Am. Chem. Soc., 2010, doi 10.1021/ja102102d.
26. G. Pandey, P. Banerjee, S. R. Gadre, Chem. Rev., 2006, 106, 4484.
27. A. Arrieta, D. Otaegui, A. Zubia, F. P. Cossío, A. Díaz-Ortiz, A. de la Hoz, M. A. Herrero, P. Prieto,
C. Foces-Foces, J. L. Pizarro, and M. I. Arriortua, J. Org. Chem., 2007, 72, 4313.
28. A. Zubia, S. Ropero, D. Otaegui, E. Ballestar, M. F. Fraga, M. Boix-Chornet, M. Berdasco, A.
Martinez, L. Coll-Mullet, J. Gil, F. P. Cossío, and M. Esteller, Oncogene, 2009, 28, 1477.
29. E. F. Pratt and S. P. Suskind, J. Org. Chem., 1963, 28, 638.
30. I. Fejes, L. Töke, G. Blaskó, M. Nyerges, and C.S. Pak, Tetrahedron, 2000, 56, 8545.
31. The Biotage SP2 HPFC systems are commercially available from Biotage AB, Kungsgatan76,
SE-753 18 Uppsala, Sweden. Website: http://www.biotage.com.
32. F. S. Baker, C. E. Miller, A. J. Repik, and E. D. Tolles, ‘Activated Carbons’ in Encyclopedia of
Separation Technology, Vol. 1, ed. by D. M. Ruthven, Wiley Interscience, New York, 1997, pp.
72-93.